The meaning of p16ink4a expression in tumors: Functional significance, clinical associations and future developments

Cell Cycle

Volumn 10, Issue 15, 2011, Pages 2497-2503

  Witkiewicz, Agnieszka K ^a,c   Knudsen, Karen E ^a,b,c   Dicker, Adam P ^a,c   Knudsen, Erik S ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

CDK; CDKN2a; Cyclin; E2F; p16; Radiation; RB; Therapy

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; RETINOBLASTOMA PROTEIN;

CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE REGULATION; GENE DISRUPTION; GENETIC CODE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 79961117100     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.15.16776     Document Type: Review

References (54)

1. Xiong Y, Zhang H, Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993; 7:1572-83; PMID: 8101826; DOI: 10.1101/gad.7.8.1572.
2. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-7; PMID: 8259215; DOI: 10.1038/366704a0.
3. Ink4a. Nature 1998; 395:237-43; PMID: 9751050; DOI: 10.1038/26155.
4. Sherr CJ. Cell cycle control and cancer. Harvey Lect 2000; 96:73-92; PMID: 12200872.
5. 1-phase progression. Genes Dev 1999; 13:1501-12; PMID: 10385618; DOI: 10.1101/gad.13.12.1501.
6. Sherr CJ, Matsushime H, Roussel MF. Regulation of CYL/cyclin D genes by colony-stimulating factor 1. Ciba Found Symp 1992; 170:209-19.
7. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499-511; PMID: 9832503; DOI: 10.1101/gad.12.22.3499.
8. Kip1regulated by mitogen- activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA 1998; 95:1091-6; PMID: 9448290; DOI: 10.1073/pnas.95.3.1091.
9. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7:331-42; PMID: 8449399; DOI: 10.1101/gad.7.3.331.
10. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF, et al. Identification and properties of an atypical catalytic subunit (p34PSK- J3/cdk4) for mammalian D type G1 cyclins. Cell 1992; 71:323-34; PMID: 1423597; DOI: 10.1016/0092-8674(92)90360-O.
11. Knudsen ES, Knudsen KE. Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med (Maywood) 2006; 231:1271-81; PMID: 16816134.
12. Blais A, Dynlacht BD. E2F-associated chromatin modifiers and cell cycle control. Curr Opin Cell Biol 2007; 19:658-62; PMID: 18023996; DOI: 10.1016/j.ceb.2007.10.003.
13. Morris EJ, Dyson NJ. Retinoblastoma protein partners. Adv Cancer Res 2001; 82:1-54; PMID: 11447760; DOI: 10.1016/S0065-230X(01)82001-7.
14. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008; 8:671-82; PMID: 18650841; DOI: 10.1038/nrc2399.
15. Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 1997; 17:5771-83; PMID: 9315635.
16. 1/S transition and S- phase progression. Genes Dev 1998; 12:2278-92; PMID: 9694794; DOI: 10.1101/gad.12.15.2278.
17. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995; 92:6289-93; PMID: 7603984; DOI: 10.1073/pnas.92.14.6289.
18. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, et al. Retinoblastoma-protein-dependent cell cycle inhibition by the tumour suppressor p16. Nature 1995; 375:503-6; PMID: 7777060; DOI: 10.1038/375503a0.
19. Chien WW, Domenech C, Catallo R, Salles G, Ffrench M. S-phase lengthening induced by p16(Ink4a) overexpression in malignant cells with wild- type pRb and p53. Cell Cycle 2010; 9:3286-96; PMID: 20703084; DOI: 10.4161/cc.9.16.12600.
20. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753-6; PMID: 8152487; DOI: 10.1038/368753a0.
21. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436-40; PMID: 8153634; DOI: 10.1126/science.8153634.
22. Liggett WH Jr, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16:1197-206; PMID: 9508208.
23. INK4 function. Nat Genet 1995; 10:114-6; PMID: 7647780; DOI: 10.1038/ng0595-114.
24. Ink4 and retinoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines. Int J Cancer 1995; 61:115-20; PMID: 7705923; DOI: 10.1002/ijc.2910610120.
25. Ink4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269:1281-4; PMID: 7652577; DOI: 10.1126/science.7652577.
26. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444:633-7; PMID: 17136093; DOI: 10.1038/nature05268.
27. INK4Ais a robust in vivo biomarker of cellular aging in human skin. Aging Cell 2006; 5:379-89; PMID: 16911562; DOI: 10.1111/j.1474-9726.2006.00231.x.
28. Ink4a. Cell 1997; 88:593-602; PMID: 9054499; DOI: 10.1016/S0092-8674(00)81902-9.
29. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, et al. Tumour biology: senescence in premalignant tumours. Nature 2005; 436:642; PMID: 16079833; DOI: 10.1038/436642a.
30. de Jonge HJ, Woolthuis CM, de Bont ES, Huls G. Paradoxical downregulation of p16 mRNA with advancing age in acute myeloid leukemia. Aging (Albany NY) 2009; 1:949-53; PMID: 20157576.
31. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436:720-4; PMID: 16079850; DOI: 10.1038/nature03890.
32. Mendenhall WM, Logan HL. Human Papillomavirus and Head and Neck Cancer. Am J Clin Oncol 2009.
33. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243:934-7; PMID: 2537532; DOI: 10.1126/science.2537532.
34. Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8:4099-105; PMID: 2556261.
35. Kelley MJ, Nakagawa K, Steinberg SM, Mulshine JL, Kamb A, Johnson BE. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst 1995; 87:756-61; PMID: 7563154; DOI: 10.1093/jnci/87.10.756.
36. Tort F, Bartkova J, Sehested M, Orntoft T, Lukas J, Bartek J. Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res 2006; 66:10258-63; PMID: 17079443; DOI: 10.1158/0008-5472.CAN-06-2178.
37. Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005; 23:3043-51; PMID: 15860862; DOI: 10.1200/JCO.2005.08.034.
38. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6:2969-72; PMID: 10955772.
39. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009; 15:294-303; PMID: 19345328; DOI: 10.1016/j.ccr.2009.02.022.
40. Campisi J. Suppressing cancer: the importance of being senescent. Science 2005; 309:886-7; PMID: 16081723; DOI: 10.1126/science.1116801.
41. Gauthier ML, Berman HK, Miller C, Kozakeiwicz K, Chew K, Moore D, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 2007; 12:479-91; PMID: 17996651; DOI: 10.1016/j.ccr.2007.10.017.
42. INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res 2001; 7:544-50; PMID: 11297246.
43. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994; 9:3375-8; PMID: 7936665.
44. Yuan J, Knorr J, Altmannsberger M, Goeckenjan G, Ahr A, Scharl A, et al. Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999; 189:358-62; PMID: 10547597; DOI: 10.1002/(SICI)1096-9896(199911)189: 3〈358::AIDPATH452〉3.0.CO;2-1.
45. + immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 2009; 33:163-75; PMID: 18936692; DOI: 10.1097/PAS.0b013e31817f9790.
46. Kong CS, Narasimhan B, Cao H, Kwok S, Erickson JP, Koong A, et al. The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009; 74:553-61; PMID: 19427557; DOI: 10.1016/j.ijrobp.2009.02.015.
47. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100:261-9; PMID: 18270337; DOI: 10.1093/jnci/djn011.
48. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363:24-35; PMID: 20530316; DOI: 10.1056/NEJMoa0912217.
49. INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28:4142-8; PMID: 20697079; DOI: 10.1200/JCO.2010.29.2904.
50. Knudsen ES, Wang JY. Targeting the RB-pathway in cancer therapy. Clin Cancer Res 2010; 16:1094-9; PMID: 20145169; DOI: 10.1158/1078- 0432.CCR-09-0787.
51. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer 2008.
52. Chakravarti A, DeSilvio M, Zhang M, Grignon D, Rosenthal S, Asbell SO, et al. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol 2007; 25:3082-9; PMID: 17634487; DOI: 10.1200/JCO.2006.08.4152.
53. nd edition). Chest 2007; 132:324-39; PMID: 17873178; DOI: 10.1378/chest.07-1385.
54. Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 2008; 10:75; PMID: 18782450; DOI: 10.1186/bcr2142.